ライフサイエンスコーパス: giant cell arteritis

1 is accurate in the initial diagnosis of GCA giant cell arteritis .

2 atory vasculopathy affecting large arteries (giant cell arteritis).

3 an isolated condition or in association with giant cell arteritis.

4 -vessel involvement in elderly patients with giant cell arteritis.

5 n the older individuals and in patients with giant cell arteritis.

6 unced in the age-related vasculitic syndrome giant cell arteritis.

7 ic infiltrates in patients with panarteritic giant cell arteritis.

8 rosis factor-alpha is present in arteries in giant cell arteritis.

9 ion of patients with large-vessel disease in giant cell arteritis.

10 ith T cells and monocytes from patients with giant cell arteritis.

11 T-cell activation and granuloma formation in giant cell arteritis.

12 tanding of the underlying pathomechanisms of giant cell arteritis.

13 ucocorticoid-free remission in patients with giant-cell arteritis.

14 ticoid tapering was studied in patients with giant-cell arteritis.

15 n show findings relevant to the diagnosis of giant-cell arteritis.

16 ant to the diagnosis of challenging cases of giant-cell arteritis.

17 ations concerning diagnosis and treatment of giant-cell arteritis.

18 Alzheimer's disease, multiple sclerosis and giant-cell arteritis.

19 Giant cell arteritis, a chronic autoimmune disease of th

20 vasculitides, such as Takayasu arteritis and giant cell arteritis, affect vital arteries and cause cl

21 istochemical and gene expression analyses of giant cell arteritis-affected temporal arteries revealed

22 se trials and other recent investigations of giant cell arteritis and idiopathic intracranial hyperte

23 continue to be the mainstay of treatment for giant cell arteritis and its complications.

24 lthough large vessel inflammatory disorders (giant cell arteritis and Takayasu arteritis) are the mos

25 ulated in inflamed arteries of patients with giant cell arteritis and Takayasu arteritis, and serum l

26 of large-vessel vasculitides, including both giant cell arteritis and Takayasu arteritis, and the aor

27 tivity vasculitis, Wegener's granulomatosis, giant cell arteritis and Takayasu's arteritis in the US

28 n clinically available tests: pentraxin-3 in giant cell arteritis and Takayasu's arteritis; von Wille

29 An unusual case of giant cell arteritis and the most significant symptoms a

30 ymptoms and 2 of 203 (1.0%) for treatment of giant cell arteritis, and 1 of 193 (0.5%) for the pathop

31 al detachment, acute angle-closure glaucoma, giant cell arteritis, and central retinal artery occlusi

32 er virus (VZV) vasculopathy produces stroke, giant cell arteritis, and granulomatous aortitis, and it

33 g from the vasculitides (Takayasu arteritis, giant cell arteritis, and polyarteritis nodosa) to ather

34 egener granulomatosis, polyarteritis nodosa, giant-cell arteritis, and hypersensitivity vasculitis on

35 f 216 respondents (5.1%; 95% CI, 2.2%-8.0%), giant cell arteritis; and 10 of 218 respondents (4.6%; 9

36 tic arthritis, polymyalgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogre

37 ostic clues in helping make the diagnosis of giant cell arteritis are discussed.

38 dia and intima where pathological changes in giant cell arteritis are most pronounced.

39 Subsets of giant cell arteritis are probably caused by variations i

40 Because intracerebral VZV vasculopathy and giant cell arteritis are strongly associated with produc

41 k factors for RAO in cardiac surgery include giant cell arteritis, carotid stenosis, stroke, hypercoa

42 Giant-cell arteritis commonly relapses when glucocortico

43 Giant cell arteritis continues to be a common cause of v

44 ological aortic involvement in patients with giant cell arteritis correlates with the significant det

45 In temporal arteries affected by giant cell arteritis, DCs are highly enriched and activa

46 disorder; multiple myeloma; acute leukemia; giant cell arteritis; dialysis; esophageal, stomach, pan

47 sculitis, systemic granulomatous vasculitis, giant cell arteritis, diverse connective tissue disorder

48 a-producing T cells in vasculitic lesions of giant cell arteritis express several markers that identi

49 This issue provides a clinical overview of giant cell arteritis, focusing on diagnosis, treatment,

50 Giant-cell arteritis frequently poses diagnostic and the

51 Giant cell arteritis (GCA) and Takayasu's arteritis (TAK

52 ermine whether an association exists between giant cell arteritis (GCA) and the presence of varicella

53 Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diso

54 Giant cell arteritis (GCA) causes autoimmune inflammatio

55 This article aims to provide a review of giant cell arteritis (GCA) clinical features, differenti

56 Granuloma formation in giant cell arteritis (GCA) emphasizes the role of adapti

57 Giant cell arteritis (GCA) is a granulomatous and occlus

58 Giant cell arteritis (GCA) is a systemic vasculitis pref

59 Giant cell arteritis (GCA) is a vasculitic syndrome that

60 Giant cell arteritis (GCA) is an immune-mediated disease

61 Giant cell arteritis (GCA) is an inflammatory vasculopat

62 Glucocorticoid (GC) therapy for giant cell arteritis (GCA) is effective but requires pro

63 Arterial wall damage in giant cell arteritis (GCA) is mediated by several differ

64 Giant cell arteritis (GCA) is the most common form of sy

65 Giant cell arteritis (GCA) is the most common form of va

66 Giant cell arteritis (GCA) is the most common systemic v

67 Giant cell arteritis (GCA) is the most common type of pr

68 ies suggest that extracranial involvement of giant cell arteritis (GCA) may be more extensive than pr

69 conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic immune-mediated

70 In giant cell arteritis (GCA), inflammatory lesions typical

71 tion between rheumatology care and age, sex, giant cell arteritis (GCA), PMR relapses, corticosteroid

72 Giant cell arteritis (GCA), the most common form of syst

73 In giant cell arteritis (GCA), vasculitic damage of the aor

74 racteristic of polymyalgia rheumatica and/or giant cell arteritis (GCA).

75 (ESR), and bilateral AION were suggestive of giant cell arteritis (GCA).

76 lasms, inflammation, pituitary apoplexy, and giant cell arteritis (GCA).

77 of adjunctive low-dose methotrexate (MTX) in giant cell arteritis (GCA).

78 d cerebrovascular accidents often complicate giant cell arteritis (GCA).

79 artery biopsies taken from individuals with giant cell arteritis (GCA).

80 Giant-cell arteritis (GCA) is a large-vessel vasculitis

81 ment of large arteries is well-documented in giant-cell arteritis (GCA), but the risk for cardiovascu

82 n the subclavian or axillary vessels; aortic giant-cell arteritis; giant-cell arteritis presenting as

83 ous arteritis characterizes the pathology of giant cell arteritis, granulomatous aortitis, and intrac

84 Giant cell arteritis has supplanted temporal arteritis a

85 biopsy (TAB), performed for the diagnosis of giant cell arteritis, has a low reported rate of complic

86 Studies in giant cell arteritis have shown that differences in the

87 and herpesviruses in temporal arteries with giant cell arteritis have yielded contradictory results.

88 Inflammation of the arterial wall in giant cell arteritis induces a series of structural chan

89 Giant cell arteritis is a granulomatous vasculitis of th

90 Visual loss caused by giant cell arteritis is a medical emergency that require

91 Giant cell arteritis is a systemic condition with a stro

92 the vascular lesions support the model that giant cell arteritis is a T-cell-driven disease.

93 Giant cell arteritis is associated with a markedly incre

94 ortic aneurysm formation in association with giant cell arteritis is discussed, along with the implic

95 Although survival in giant cell arteritis is generally good, subsets of patie

96 rticoid-induced remission of newly diagnosed giant cell arteritis is of no benefit and may be harmful

97 Giant-cell arteritis is an immune-mediated disease chara

98 Giant-cell arteritis is associated with increased risks

99 In general, the clinical outcome of giant-cell arteritis is excellent, and efforts must now

100 In other vascular territories, giant-cell arteritis is most commonly diagnosed by vascu

101 es are discussed here, and scalp necrosis in giant-cell arteritis is reviewed.

102 -positive results than in patients with GCA giant cell arteritis -negative results ( TAB temporal ar

103 Large-vessel involvement in giant cell arteritis occurs in over a quarter of patient

104 Associated with increased RAO were giant cell arteritis (odds ratio [OR], 7.73; CI, 2.78-21

105 tokine transcription in temporal arteries of giant cell arteritis patients with and without up-regula

106 re significantly higher in patients with GCA giant cell arteritis -positive results than in patients

107 illary vessels; aortic giant-cell arteritis; giant-cell arteritis presenting as an intense systemic i

108 As in giant cell arteritis, recent evidence supports the role

109 Most frequently encountered are giant cell arteritis (temporal arteritis) and vasculitis

110 o study the regulation of neoangiogenesis in giant cell arteritis, temporal arteries were examined fo

111 ive criteria for a positive biopsy result in giant cell arteritis, the imaging characteristics of pri

112 reports have highlighted etiologies such as giant cell arteritis, trauma, neuro-syphilis and demyeli

113 00 have polymyalgia rheumatica, 228,000 have giant cell arteritis, up to 3.0 million have had self-re

114 Giant cell arteritis was also identified in 5 patients.

115 GCA giant cell arteritis was diagnosed or excluded clinicall

116 Temporal artery specimens from patients with giant cell arteritis were analyzed bu two-color immunohi

117 onsent, 185 patients suspected of having GCA giant cell arteritis were included in a prospective thre

118 rely affect the temporal arteries, mimicking giant cell arteritis, while, to our knowledge, the assoc

119 nical subtypes can be distinguished: cranial giant-cell arteritis with ischemic complications in the

120 and the central nervous system; large-vessel giant-cell arteritis with occlusions in the subclavian o

121 rease likelihood of stroke or visual loss in giant-cell arteritis without increasing bleeding complic